Jonna Alanko

Sep 8, 2023 | science.org | Giacomo Oliveira |Jonna Alanko |Paul Brennan

Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsSubmission historyReceived: 15 February 2023Accepted: 8 August 2023PermissionsRequest permissions for this article. AcknowledgmentsWe thank E. Dissen (University of Oslo, Norway) for providing KIR2DS1 reporter cells. Funding: This work was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. Author contributions: M.J.W.S. and E.O.L. conceived the study.

Sep 8, 2023 | sciencemag.org | Giacomo Oliveira |Jonna Alanko |Paul Brennan

Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsSubmission historyReceived: 15 February 2023Accepted: 8 August 2023PermissionsRequest permissions for this article. AcknowledgmentsWe thank E. Dissen (University of Oslo, Norway) for providing KIR2DS1 reporter cells. Funding: This work was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. Author contributions: M.J.W.S. and E.O.L. conceived the study.

Sep 1, 2023 | science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Nisha Saif

Editors' ChoiceFOCIS HIGHLIGHTS It is estimated that at least 1 in 5 people infected with COVID-19 are asymptomatic. Despite the central role of human leukocyte antigen (HLA) variation in susceptibility to viral infection, relatively little is understood about its role in conferring protection against symptomatic COVID-19 disease. To shed light on this important question, Augusto et al.

Sep 1, 2023 | science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai

Editors' ChoiceFOCIS HIGHLIGHTS Immunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.

Sep 1, 2023 | science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Elena Mandrou

Published In Science ImmunologyVolume 8 | Issue 87September 2023Article versionsPermissionsRequest permissions for this article. AcknowledgmentsFunding: This work was funded by core grant A24450 from Cancer Research UK, Programme Grant MR/X000702/1 from the Medical Research Council (MRC), and Wellcome Investigator grant 221786/Z/20/Z to R.I.Author contributions: H.D., E.M., and R.I. wrote the manuscript. Competing interests: The authors declare that they have no competing interests.